Canadian Pharma, Biotech and Life Sciences Stocks

Canopy Growth Corp. is the clear market leader but its stock is overpriced, says Beacon Securities

Canopy Growth Corp. CEO Bruce Linton. With pot-growing facilities lined up in every province and supply deals secured in four of them, Canopy Growth Corp. (TSX:WEED) stands as the clear leader in the run-up to recreational marijuana’s start date, says analyst Vahan Ajamian with Beacon Securities ...

Acasti Pharma has 194% upside, Echelon Wealth says

All eyes will be on upcoming Phase III drug trials for Acasti Pharma’s (TSXV:ACST) cardiovascular drug, CaPre, which could be a big revenue generator, says analyst Douglas Loe of Echelon Wealth Partners, who maintains his “Speculative Buy” rating on the stock and a target price of $4.00. Lava ...

Canopy Growth Corp’s Quebec cannabis deal gets thumbs up at GMP

A deal to supply marijuana to Quebec overshadows what GMP Securities analyst Martin Landry describes as “mixed” third quarter results for Canopy Growth Corp. (TSX:WEED). This morning, Canopy Growth reported its Q3, 2018 results. The company earned $11.01-million on revenue of $21.7-million, a ...

Hamilton Thorne is undervalued, says Beacon Securities in coverage launch

Hamilton Thorne (TSXV:HTL) is well-positioned to benefit from the growth in In-Vitro Fertilization (IVF) clinics worldwide, making its stock a cheap pickup, says Beacon Securities analyst Doug Cooper, who has initiated coverage of the company with a “Buy” rating and a $1.40 target price. A manu ...

Canopy Growth Corp. is set to be a dominant global cannabis player, Canaccord Genuity says

Emerging evidence that the international ambitions of Canopy Growth Corp. (TSX:WEED) are progressing faster than expected has Canaccord Genuity analyst Neil Maruoka raising his target price on the stock, though the analyst is still not recommending investors buy the stock at current levels. Maruok ...

Canopy Growth Corp. is worth just $13.00 a share, Echelon Wealth says

Shares of Canopy Growth Corp. (TSX:WEED) have fallen sharply in 2018, but would-be bargain hunters should continue to treat the stock with caution, Echelon Wealth Partners analyst Russell Stanley says. On February 7, Canopy Growth Corp.announced it had completed a previously announced bought deal ...

Supreme Cannabis is ready to become a market leader, GMP Securities says

Premium bud-grower Supreme Cannabis Company (FIRE:TSXV) is in line to distinguish itself from the herd of cannabis contenders, says Robert Fagan of GMP Securities, who Thursday initiatied coverage of Supreme with a “Buy” rating. Tiny Kincardine, Ontario, on the shores of Lake Huron is home to ...

Is Canopy Growth Corp. losing its lead as cannabis king?

Canopy Growth Corp. (TSX:WEED) has long played the role of heavyweight champion of the weed sector Canada, but with recent moves by two of its closest rivals, is Canopy in danger of losing its crown? We delved into data from Google Trends and found that this likely not the case. Since the race beg ...

Legalization delays mean added uncertainty for pot stocks, Echelon says

Now we play the waiting game. The timeline to pot legalization in Canada has been stretched out to late summer and possibly early fall, according to a new statement from the federal government, which plans to introduce an eight-to-12 week transition period after legislation has been passed. Inten ...

Three reasons to be bullish about Canopy Growth Corp. from GMP Securities

Canopy CEO Bruce Linton. With its most recent equity financing complete, GMP Securities analyst Martin Landry has resumed coverage of Canopy Growth Corp. (TSX:WEED) with the same bullish target. On Wednesday, Canopy announced it had completed a previously announced bought deal worth just over $20 ...